Advertisement

Inflammation

, Volume 37, Issue 5, pp 1608–1615 | Cite as

Ginsenoside Metabolite Compound K Alleviates Adjuvant-Induced Arthritis by Suppressing T Cell Activation

  • Jingyu Chen
  • Huaxun Wu
  • Qingtong Wang
  • Yan Chang
  • Kangkang Liu
  • Shasha Song
  • Pingfan Yuan
  • Jingjing Fu
  • Wuyi Sun
  • Qiong Huang
  • Lihua Liu
  • Yujing Wu
  • Yunfang Zhang
  • Aiwu Zhou
  • Wei WeiEmail author
Article

Abstract

Ginsenoside metabolite compound K (CK) is the degradation product of ginsenosides in the intestine by bacteria and has many pharmacological activities including anti-inflammatory effects. Rheumatoid arthritis (RA) is an inflammatory and autoimmune disease characterized by chronic synovial inflammation and articular damage in multiple joints. However, the effect of CK on RA remains unclear. In this study, the effect of CK on adjuvant arthritis (AA) and the underlying mechanisms that focused on T cell activation were investigated. Complete Freund’s adjuvant was used to induce AA rats. After the onset of arthritis, rats were given CK (10, 40, and 160 mg/kg) or MTX (0.5 mg/kg). To evaluate the severity of arthritis, arthritis index and paw swelling were evaluated every 3 days. Histopathology of joint and spleen were assayed. Subsets of T cells including CD4 + CD62L+ (naïve T cells), CD4 + CD25+ (activated T cells), and CD4 + CD25 + Foxp3+ cells (Treg) and CD25 expression were assayed by flow cytometry. Proliferation of T cell was evaluated by 3H-TdR. IL-2 level was assayed by ELISA. We found that CK attenuated arthritis index and paw swelling, restored the histopathological change of joint and spleen, downregulated the percentage of activated T cells, and upregulated naïve T cells and Treg cells in spleen. CK significantly suppressed T cell activation (as indicated by T cell proliferation, CD25 expression, and IL-2 production). In conclusion, our results suggest that CK alleviates autoimmune arthritis by suppressing T cell activation.

KEY WORDS

ginsenoside metabolite compound K adjuvant-induced arthritis T cell activation CD25 IL-2 regulatory T cells 

Notes

ACKNOWLEDGMENTS

This work was financially supported by the National Nature Science Foundation of China (Nos. 30973543, 81173075, 81330081, and 31200675), Anhui Province Nature Science Foundation in the University (No. KJ2011Z180), Foundation for Outstanding Young Talents in Higher Education Institutions of Anhui Province (No. 2012SQRL268), and Anhui Provincial Natural Science Foundation (No. 1208085QH158).

Conflict of Interest

The authors declare that there are no conflicts of interest.

REFERENCES

  1. 1.
    Carmona, L., M. Cross, B. Williams, M. Lassere, and L. March. 2010. Rheumatoid arthritis. Best Practice & Research. Clinical Rheumatology 24(6): 733–745.CrossRefGoogle Scholar
  2. 2.
    Rodeghero, R., Y. Cao, S.A. Olalekan, Y. Iwakua, T.T. Glant, and A. Finnegan. 2013. Location of CD4+ T cell priming regulates the differentiation of Th1 and Th17 cells and their contribution to arthritis. Journal of Immunology 190(11): 5423–5435.CrossRefGoogle Scholar
  3. 3.
    Lundy, S.K., S. Sarkar, L.A. Tesmer, and D.A. Fox. 2007. Cells of the synovium in rheumatoid arthritis. T lymphocytes. Arthritis Research and Therapy 9(1): 202.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Rogers, J.L., D.S. Serafin, R.G. Timoshchenko, and T.K. Tarrant. 2012. Cellular targeting in autoimmunity. Current Allergy and Asthma Reports 12(6): 495–510.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Martin, R. 2012. Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis. Clinical Immunology 142(1): 9–14.PubMedCrossRefGoogle Scholar
  6. 6.
    Chang, Y., Y. Wu, D. Wang, W. Wei, Q. Qin, G. Xie, L. Zhang, S. Yan, J. Chen, Q. Wang, H. Wu, F. Xiao, W. Sun, J. Jin, and W. Wang. 2011. Therapeutic effects of TACI-Ig on rats with adjuvant-induced arthritis via attenuating inflammatory responses. Rheumatology (Oxford) 50(5): 862–870.CrossRefGoogle Scholar
  7. 7.
    Song, S.S., B. Huang, Q.T. Wang, Y.J. Wu, J.J. Fu, Y.F. Zhang, Y. Chang, J.Y. Chen, H.X. Wu, D. Wang, L.L. Zhang, and W. Wei. 2013. BF02, a recombinant TNFR2 fusion protein, alleviates adjuvant arthritis by regulating T lymphocytes in rats. Acta Pharmacologica Sinica 34(3): 414–423.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Chi, H., and G.E. Ji. 2005. Transformation of ginsenosides Rb1 and Re from Panax ginseng by food microorganisms. Biotechnological Letters 27(11): 765–771.CrossRefGoogle Scholar
  9. 9.
    Tawab, M.A., U. Bahr, M. Karas, M. Wurglics, and M. Schubert-Zsilavecz. 2003. Degradation of ginsenosides in humans after oral administration. Drug Metabolism and Disposition 31(8): 1065–1071.PubMedCrossRefGoogle Scholar
  10. 10.
    Joh, E.H., I.A. Lee, I.H. Jung, and D.H. Kim. 2011. Ginsenoside Rb1 and its metabolite compound K inhibit IRAK-1 activation—the key step of inflammation. Biochemical Pharmacology 82(3): 278–286.PubMedCrossRefGoogle Scholar
  11. 11.
    Park, E.K., Y.W. Shin, H.U. Lee, S.S. Kim, Y.C. Lee, B.Y. Lee, and D.H. Kim. 2005. Inhibitory effect of ginsenoside Rb1 and compound K on NO and prostaglandin E2 biosyntheses of RAW264.7 cells induced by lipopolysaccharide. Biological and Pharmaceutical Bulletin 28(4): 652–656.PubMedCrossRefGoogle Scholar
  12. 12.
    Yang, C.S., S.R. Ko, B.G. Cho, D.M. Shin, J.M. Yuk, S. Li, J.M. Kim, R.M. Evans, J.S. Jung, D.K. Song, and E.K. Jo. 2008. The ginsenoside metabolite compound K, a novel agonist of glucocorticoid receptor, induces tolerance to endotoxin-induced lethal shock. Journal of Cellular and Molecular Medicine 12(5A): 1739–1753.PubMedCrossRefGoogle Scholar
  13. 13.
    Choy, E.H., and G.S. Panayi. 2001. Cytokine pathways and joint inflammation in rheumatoid arthritis. New England Journal of Medicine 344(12): 907–916.PubMedCrossRefGoogle Scholar
  14. 14.
    Létourneau, S., C. Krieg, G. Pantaleo, and O. Boyman. 2009. IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. Journal of Allergy and Clinical Immunology 123(4): 758–762.PubMedCrossRefGoogle Scholar
  15. 15.
    Laurence, A., C.M. Tato, T.S. Davidson, Y. Kanno, Z. Chen, Z. Yao, R.B. Blank, F. Meylan, R. Siegel, L. Hennighausen, E.M. Shevach, and J.J. O'shea. 2007. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26(3): 371–381.PubMedCrossRefGoogle Scholar
  16. 16.
    Cote-Sierra, J., G. Foucras, L. Guo, L. Chiodetti, H.A. Young, J. Hu-Li, J. Zhu, and W.E. Paul. 2004. Interleukin 2 plays a central role in Th2 differentiation. Proceedings of the National Academy of Sciences of the United States of America 101(11): 3880–3885.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Kovanen, P.E., and W.J. Leonard. 2004. Cytokines and immunodeficiency diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunological Reviews 202: 67–83.PubMedCrossRefGoogle Scholar
  18. 18.
    Dooms, H., E. Kahn, B. Knoechel, and A.K. Abbas. 2004. IL-2 induces a competitive survival advantage in T lymphocytes. Journal of Immunology 172(10): 5973–5979.CrossRefGoogle Scholar
  19. 19.
    Dooms, H., K. Wolslegel, P. Lin, and A.K. Abbas. 2007. Interleukin-2 enhances CD4+ T cell memory by promoting the generation of IL-7R alpha-expressing cells. Journal of Experimental Medicine 204(3): 547–557.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Brok, H.P., J.M. Tekoppele, J. Hakimi, J.A. Kerwin, E.M. Nijenhuis, C.W. De Groot, R.E. Bontrop, and B.A. ‘t Hart. 2001. Prophylactic and therapeutic effects of a humanized monoclonal antibody against the IL-2 receptor (DACLIZUMAB) on collagen-induced arthritis (CIA) in rhesus monkeys. Clinical and Experimental Immunology 124(1): 134–141.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Mijnheer, G., B.J. Prakken, and F. van Wijk. 2013. The effect of autoimmune arthritis treatment strategies on regulatory T-cell dynamics. Current Opinion in Rheumatology 25(2): 260–267.PubMedCrossRefGoogle Scholar
  22. 22.
    Ehrenstein, M.R., J.G. Evans, A. Singh, S. Moore, G. Warnes, D.A. Isenberg, and C. Mauri. 2004. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. Journal of Experimental Medicine 200(3): 277–285.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Buckner, J.H. 2010. Mechanisms of impaired regulation by CD4+CD25+FOXP3+ regulatory T cells in human autoimmune diseases. Nature Reviews Immunology 10: 849–859.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Frey, O., P.K. Petrow, M. Gajda, K. Siegmund, J. Huehn, A. Scheffold, A. Hamann, A. Radbruch, and R. Bräuer. 2005. The role of regulatory T cells in antigen-induced arthritis: aggravation of arthritis after depletion and amelioration after transfer of CD4+CD25+ T cells. Arthritis Research and Therapy 7(2): R291–R301.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Kong, N., Q. Lan, M. Chen, T. Zheng, W. Su, J. Wang, Z. Yang, R. Park, G. Dagliyan, P.S. Conti, D. Brand, Z. Liu, H. Zou, W. Stohl, and S.G. Zheng. 2012. Induced T regulatory cells suppress osteoclastogenesis and bone erosion in collagen-induced arthritis better than natural T regulatory cells. Annals of the Rheumatic Diseases 71(9): 1567–1572.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Shevach, E.M. 2009. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 30(5): 636–645.PubMedCrossRefGoogle Scholar
  27. 27.
    Wing, K., Z. Fehérvári, S. Sakaguchi, K. Wing, Z. Fehervari, and S. Sakaguchi. 2006. Emerging possibilities in the development and function of regulatory T cells. International Immunology 18(7): 991–1000.PubMedCrossRefGoogle Scholar
  28. 28.
    Wu, H., J. Chen, Q. Wang, X. Jia, S. Song, P. Yuan, K. Liu, L. Liu, Y. Zhang, A. Zhou, and W. Wei. 2014. Ginsenoside metabolite compound K attenuates inflammatory responses of adjuvant-induced arthritis rats. Immunopharmacology and Immunotoxicology Google Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Jingyu Chen
    • 1
  • Huaxun Wu
    • 1
  • Qingtong Wang
    • 1
  • Yan Chang
    • 1
  • Kangkang Liu
    • 1
  • Shasha Song
    • 1
  • Pingfan Yuan
    • 1
  • Jingjing Fu
    • 1
  • Wuyi Sun
    • 1
  • Qiong Huang
    • 1
  • Lihua Liu
    • 1
  • Yujing Wu
    • 1
  • Yunfang Zhang
    • 1
  • Aiwu Zhou
    • 1
  • Wei Wei
    • 1
    Email author
  1. 1.Clinical Pharmacology Institute, Key Laboratory of Antiinflammatory and Immune Medicine, Ministry of EducationAnhui Medical UniversityHefeiChina

Personalised recommendations